Therapy and new therapeutic agent for blood cancer
AssigneeDelta-Fly Pharma, Inc.
InventorsTatsuhiro Ishida, Kiyoshi Eshima
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.
Claims8
A combined medicine, comprising 4-amino-1-(2-cyano-2-deoxy-(3-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof in a dosage form for continuous intravenous infusion in an amount sufficient to provide an amount from 1 to 10 mg per 1 m2 of body surface area of a patient per day over 168 to 336 hours, said patient having a blood cancer, and venetoclax or a salt thereof in a dosage form for oral administration to the patient.
A method for treating or ameliorating blood cancer, comprising administering to a patient with blood cancer 4-amino-1-(2-cyano-2-deoxy-(3-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof by way of continuous intravenous infusion, in an amount from 1 to 10 mg per 1 m2 of body surface area of the patient per day over 168 to 336 hours and venetoclax or a salt thereof orally.
Dependencies are inferred from the claim text.